ABVC has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ABVC has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Debt-to-EBITDA measures a company's ability to pay off its debt.
ABVC BioPharma's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $2.18 Mil. ABVC BioPharma's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $0.14 Mil. ABVC BioPharma's annualized EBITDA for the quarter that ended in Sep. 2024 was $0.37 Mil. ABVC BioPharma's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2024 was 6.25.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's
The historical rank and industry rank for ABVC BioPharma's Debt-to-EBITDA or its related term are showing as below:
During the past 13 years, the highest Debt-to-EBITDA Ratio of ABVC BioPharma was -0.20. The lowest was -1.32. And the median was -0.28.
The historical data trend for ABVC BioPharma's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ABVC BioPharma Annual Data | |||||||||||||||||||||
Trend | Sep14 | Sep15 | Sep16 | Sep17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Debt-to-EBITDA | Get a 7-Day Free Trial | -1.32 | -0.63 | -0.28 | -0.20 | -0.28 |
ABVC BioPharma Quarterly Data | ||||||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | |
Debt-to-EBITDA | Get a 7-Day Free Trial | -0.40 | -0.28 | -0.18 | -0.54 | 6.25 |
For the Biotechnology subindustry, ABVC BioPharma's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, ABVC BioPharma's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where ABVC BioPharma's Debt-to-EBITDA falls into.
Debt-to-EBITDA measures a company's ability to pay off its debt.
ABVC BioPharma's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as
Debt-to-EBITDA | = | Total Debt | / | EBITDA | ||
= | (Short-Term Debt & Capital Lease Obligation | + | Long-Term Debt & Capital Lease Obligation) | / | EBITDA | |
= | (1.871 | + | 0.407) | / | -8.132 | |
= | -0.28 |
ABVC BioPharma's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2024 is calculated as
Debt-to-EBITDA | = | Total Debt | / | EBITDA | ||
= | (Short-Term Debt & Capital Lease Obligation | + | Long-Term Debt & Capital Lease Obligation) | / | EBITDA | |
= | (2.184 | + | 0.142) | / | 0.372 | |
= | 6.25 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Sep. 2024) EBITDA data.
ABVC BioPharma (NAS:ABVC) Debt-to-EBITDA Explanation
In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.
Be Aware
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's
Thank you for viewing the detailed overview of ABVC BioPharma's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Shuling Jiang | director, 10 percent owner | 44370 OLD WARM SPRINGS BLVD., FREMONT CA 94538 |
Shih-chen Tseng | director | 5F., NO. 41-1, LN. 12, SINDONG ST., SONGSHAN DIST, TAIPEI CITY F5 105065 |
Yoshinobu Odaira | director | 4823 DUNDAS STREET, THOMDALE, LONDON X0 N6P 1J1 |
Norimi Sakamoto | director | 4823 DUNDAS STREET, THRONDALE, LONDON X0 N6P 1J1 |
Shin-yu Miao | director | NO. 25-12, AMLIN RD., XITUN DIST., TAICHUNG CITY F5 407676 |
Tsung Shann Jiang | director, officer: CSO and Director | 1197 LA PLURISSIMA PL, FREMONT CA 94539 |
Eugene Jiang | director, officer: Chairman of the Board & CBO | 1197 LA PLURISSIMA PL, FREMONT CA 94539 |
Chang-jen Jiang | director | 1197 LA PLURISSIMA PL, FREMONT CA 94539 |
Yen-hsin Chou | director | 13F. NO. 2, MEISHU E. 8TH ST.,, GUSHAN DIST., KAOHSIUNG CITY F5 804413 |
Chi-hsin Richard King | officer: Chief Scientific Officer | 11907 GRANT PLACE, SAINT LOUIS MO 63131 |
Howard Doong | officer: Chief Executive Officer | 44370 OLD WARM SPRINGS BLVD., FREMONT CA 94538 |
Chihliang An | officer: Chief Financial Officer | 32458 JEAN DR, UNION CITY CA 94587 |
Tsang Ming Jiang | director | 1197 LA PURISSIMA PL, FREMONT CA 94539 |
Shulamit Lazar | director, 10 percent owner, officer: President,Secretary,Treasurer | 8605 SANTA MONICA BOULEVARD, SUITE 41336, LOS ANGELES CA 90069 |
Kevin Patrick Stolz | officer: CFO & Controller | 2701 CAMBRIDGE COURT, SUITE 100, AUBURN HILLS MI 48326 |
From GuruFocus
By Marketwired • 06-26-2023
By Marketwired • 04-10-2024
By Marketwired • 07-27-2023
By Marketwired • 08-07-2023
By Marketwired • 11-14-2024
By Marketwired • 10-17-2023
By Marketwired • 10-09-2023
By sperokesalga sperokesalga • 02-28-2023
By Marketwired • 08-10-2023
By Marketwired • 04-18-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.